Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05426122
Other study ID # 6239222600
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 9, 2022
Est. completion date July 14, 2022

Study information

Verified date July 2022
Source Wageningen University and Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to assess the degree of digestibility of barley rice protein and compare this to another sustainable, commercially available protein concentrate (pea protein), and a benchmark whey protein, and to assess the effects on blood glucose and insulin levels. The study is a randomized, cross-over, double blind, controlled trial. Three different treatments, all representing a 20g protein load, will be evaluated with a washout period of minimum one week between the test days. Blood will be collected via a catheter before and up-to five hours after protein consumption. Wellbeing, health complaints or other adverse effects will be collected via a short questionnaire during each test day. After each test day gastrointestinal complaints are collected via an online questionnaire.


Description:

Barley rice protein is extracted from brewer spent grains (BSG), which is the most voluminous by-product of the brewing industry. Until now, BSG has been mainly used for animal feed or is directly discarded, which is an enormous waste of resources and causes serious environmental pollution. BSG is rich in cellulose and non-cellulosic polysaccharides, lignin, and proteins. The protein fraction of BSG contains a relatively high content of the essential amino acid, lysine, in comparison to other cereal products. Because of its high nutritional content, BSG can be applied in human food products for fortification. The digestion characteristics of barley rice protein are not known, but essential to evaluate their future potential as a sustainable protein source. The primary objective is to estimate the degree of digestibility of barley rice protein by measuring post-prandial amino acid uptake kinetics, and compare this to pea protein and a benchmark protein (whey). Secondary objectives are to assess the effects on blood glucose and insulin levels. The study is a randomized, cross-over, double blind, controlled trial. Three different treatments, all representing a 20g protein load, will be evaluated with a washout period of minimum one week between the test days. Blood will be collected via a catheter before and up-to five hours after protein consumption. Wellbeing, health complaints or other adverse effects will be collected via a short questionnaire during each test day. After each test day gastrointestinal complaints are collected via an online questionnaire.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date July 14, 2022
Est. primary completion date July 14, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Apparently healthy men and women; - Age between 18 and 40 years; - Body mass index (BMI) between 18.5 and 30 kg/m2 ; - Having veins suitable for blood sampling via a catheter (judged by study nurse/ medical doctor). Exclusion Criteria: - Any metabolic, gastrointestinal, inflammatory or chronic disease (such as diabetes, anaemia, hepatitis, cardiovascular disease),or having a condition or disease that may lead to an impaired immune system; - History of gastrointestinal surgery or having (serious) gastrointestinal complaints; - History of liver dysfunction (cirrhosis, hepatitis) or liver surgery; - Kidney dysfunction (self-reported); - Any use of medication that may suppress the immune system, this will be judged by the medical supervisor; - Use of medication that may influence the study results, such as gastric acid inhibitors, laxatives, stomach protectors and drugs that can affect intestinal motility, this will be judged by the medical supervisor; - Anaemia (Hb values <7.5 mmol/L for women and <8.5 mmol/L for men); - Reported slimming, medically prescribed or other extreme diets; - Use of protein supplements; - Not willing to give up blood donation during the study; - Current smokers; - Alcohol intake =4 glasses of alcoholic beverages per day; - Pregnant, lactating or wishing to become pregnant in the period of the study (self-reported); - Abuse of hard drugs; - Having food allergies and/or intolerances (e.g. for gluten); - Not having a general practitioner; - Participation in another clinical trial at the same time; - Being an employee of the department Food, Health & Consumer Research of Wageningen Food & Biobased Research.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Barley rice protein concentrate shake
At one out of three test days barley rice protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
Pea protein concentrate shake
At one out of three test days pea protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
Whey protein concentrate shake
At one out of three test days whey protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.

Locations

Country Name City State
Netherlands Stichting Wageningen Research Wageningen Gelderland

Sponsors (1)

Lead Sponsor Collaborator
Wageningen University and Research

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in degree of digestibility In order to assess change in the degree of digestibility, we determine 19 free amino acids in blood samples collected via a catheter before and at several time points up-to five hours after protein source consumption. Blood amino acids will be determined by the laboratory of Wageningen FBR, according a valid method: AccQ-Tag ultra-derivation kit & HPLC. During the intervention period on 3 test days: at baseline and postprandial blood samples will be collected from the cannula at 10 time points (T=0, 30, 45, 60, 90, 120, 150, 180, 240, 300 minutes)
Secondary Change in plasma glucose levels Plasma glucose levels will be determined in blood samples collected via a catheter before and at several time points up-to five hours after protein source consumption (hospital laboratory Ziekenhuis Gelderse vallei, Ede, the Netherlands) During the intervention period on 3 test days: at baseline and postprandial blood samples will be collected from the cannula at 10 time points (T=0, 30, 45, 60, 90, 120, 150, 180, 240, 300 minutes)
Secondary Change in plasma insulin levels Plasma insulin levels will be determined in blood samples collected via a catheter before and at several time points up-to five hours after protein source consumption (hospital laboratory Ziekenhuis Gelderse vallei, Ede, the Netherlands). During the intervention period on 3 test days: at baseline and postprandial blood samples will be collected from the cannula at 10 time points (T=0, 30, 45, 60, 90, 120, 150, 180, 240, 300 minutes)
See also
  Status Clinical Trial Phase
Completed NCT00671177 - Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique N/A
Completed NCT05118412 - Personal Protein Digestion Variability N/A
Not yet recruiting NCT06396728 - Use of GI BIOTICS 100B UFC to Improve Intestinal Health in Older Adults N/A
Completed NCT04819789 - Digestibility of Fermotein™ N/A